HOME >> BIOLOGY >> NEWS
JCI Table of Contents, 15 August 2003

Anti-asthma medications: too much of a good thing?

In an unusual paradox, asthmatics that are chronically treated with bronchodilating beta-agonist medications such as albuterol, ventolin, and salbutamol may ultimately develop increased sensitivity to airway constriction and experience exacerbation of their condition. A new study by Stephen Liggett and colleagues at the University of Cincinnati in the August 15 issue of the Journal of Clinical Investigation describes a responsible mechanism for this adverse reaction and reveals a potential new therapeutic target in the treatment of asthma.

Inhaled selective beta-agonists are the most widely used treatment for the acute relief of asthma symptoms. Administered to asthmatic patients via an inhaler, nebulizer, in tablet or liquid form, or injection, they cause airway relaxation and reduced airway responsiveness to nonspecific contractile stimuli. This is achieved by drug binding to the beta2-adrenergic receptor (beta2AR). Despite the ability of these agents to immediately reverse airway obstruction, there has been ongoing concern that the use of these drugs may be associated with harmful outcomes. Some, but not all, studies have revealed that regular scheduled use (e.g., multiple times daily, every day) of inhaled beta-agonists has resulted in a loss of control over the condition, which can manifest as longer asthmatic attacks and and post-treatment airway hyperresponsiveness.

To date, the evidence has suggested that a desensitization of the beta2AR is responsible. Liggett and colleagues suggest an alternative explanation. The authors demonstrate that persistent high-level activation of the beta2AR leads to increased expression of phospholipase C-beta (PLC-beta) in airway smooth muscle, inducing a crosstalk between beta2AR signaling pathways that ultimately results in airway hyperresponsiveness.

In their accompanying commentary, Stephanie Shore and Jeffrey Drazen from the Harva
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
15-Aug-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2018)... ... August 13, 2018 , ... NRD, LLC – NRD® is ... Ionizing Gun. , The ionizing gun features ergonomic design and rugged construction. ... filter and electropolished OSHA-compliant tip. This can be cleanroom packaged (P-2021-5502) or normally ...
(Date:8/14/2018)... ... August 14, 2018 , ... From ... movie “Wonder,” to a better understanding of congenital heart defects, 3-D printing is ... the latest special issue of Birth Defects Research (DOI: 10.1002/bdr2.1367). ...
(Date:8/7/2018)... ... 06, 2018 , ... Nurse practitioners and ... their healthcare careers in the past year, according to the second annual survey ... jobseekers with a wide variety of career- and employment-related resources including physician/candidate database, ...
Breaking Biology News(10 mins):
(Date:7/24/2018)... ... ... R3 Stem Cell is now offering regenerative therapies for COPD lung disease ... Certified providers, with outcomes significantly improving patient quality of life. , Traditional therapies for ... help repair and regenerate damaged lung tissues. Stem cell therapy for COPD ...
(Date:7/24/2018)... ... 24, 2018 , ... On August 6, 2018, BioMedGPS will ... Not just a pretty face, SmartTRAK 3.0’s latest improvements were inspired by its ... world’s first online and real-time data portal that specializes in providing competitive market ...
(Date:7/22/2018)... ... July 19, 2018 , ... Mitotech ... with Essex Bio-Investment for Phase 3 clinical program in Dry Eye Disease. Under ... SkQ1 with approximately $17m allocated towards the first Phase 3 study starting as ...
(Date:7/22/2018)... ... July 20, 2018 , ... ... automation and IT solutions with 150 employees on both the east and west ... Program. Superior Controls met the high criteria for application expertise, operational excellence ...
Breaking Biology Technology:
Cached News: